Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Change in Accured Expenses (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of Change in Accured Expenses data on record, last reported at -$11.1 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 122.71% year-over-year to -$11.1 million; the TTM value through Sep 2025 reached -$9.9 million, down 36.54%, while the annual FY2024 figure was -$6.4 million, 712.98% down from the prior year.
  • Change in Accured Expenses reached -$11.1 million in Q3 2025 per FBIO's latest filing, down from -$86000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $34.0 million in Q3 2021 and bottomed at -$33.9 million in Q4 2021.
  • Average Change in Accured Expenses over 5 years is -$943526.3, with a median of -$47000.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 4856.52% in 2022, then tumbled 602.82% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$33.9 million in 2021, then skyrocketed by 86.43% to -$4.6 million in 2022, then skyrocketed by 96.78% to -$148000.0 in 2023, then soared by 591.89% to $728000.0 in 2024, then crashed by 1626.51% to -$11.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$11.1 million in Q3 2025, -$86000.0 in Q2 2025, and $550000.0 in Q1 2025.